CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dahaba, A. A.
Right arrow Articles by List, W. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dahaba, A. A.
Right arrow Articles by List, W. F.

Canadian Journal of Anesthesia, Vol 46, 696-700, Copyright © 1999 by Canadian Anesthesiologists' Society

ARTICLES

Total intravenous anesthesia with remifentanil, propofol and cisatracurium in end-stage renal failure

AA Dahaba, F von Klobucar, PH Rehak and WF List
Department of Anesthesiology and Intensive Care Medicine, Karl-Franzens University, Graz, Austria.

PURPOSE: To compare recovery parameters of total intravenous anesthesia (TIVA) with remifentanil and propofol, hemodynamic responses to perioperative events, and pharmacodynamic parameters of cisatracurium in 22 end-stage renal failure and 22 normal renal function patients. METHODS: Anesthesia was induced with 2-3 mg x kg(-1) propofol and 1 microg x kg(-1) remifentanil and maintained with 75 microg x kg(-1) x min(-1) propofol and propofol initial infusion of 0.2 microg x kg(-1) x min(-1) propofol. Arterial pressure and heart rate were maintained by remifentanil infusion rate adjustments. The first twitch (T1) was maintained at 25% by an infusion of cisatracurium. RESULTS: There was no difference in the time to maintenance of adequate respiration, date of birth recollection, first analgesic administration, between the renal failure (4.8+/-2.5, 7.8+/-3.2, 12.3+/-5.3 min respectively) and the control group (5.2+/-2.8, 8.1+/-3.1, 12.7+/-5.5 min): nor were there any differences in the time to 25% T1 recovery, T1 recovery from 25% to 75%, or cisatracurium infusion rate between the renal failure group (32.1 +/-10.8 min, 18.2+/-5.5 min, 0.89+/-0.29 microg x kg(-1) min(-1) respectively) and the control group (35.9 (7.9 min, 18.4+/-3.8 min, 0.95+/-0.22 microg x kg(-1) x min(-1)). CONCLUSION: End-stage renal failure does not prolong recovery from TIVA with remifentanil and propofol, or the recovery from cisatracurium neuromuscular block.


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
R. G. Craig and J. M. Hunter
Recent developments in the perioperative management of adult patients with chronic kidney disease
Br. J. Anaesth., September 1, 2008; 101(3): 296 - 310.
[Abstract] [Full Text] [PDF]

Home page
 Canadian J. AnesthesiaHome page
A. A. Dahaba, K. Oettl, F. von Klobucar, G. Reibnegger, and W. F. List
End-stage renal failure reduces central clearance and prolongs the elimination half life of remifentanil: [L'insuffisance renale terminale reduit la clairance centrale et prolonge la demi-vie d'elimination du remifentanil]
Can J Anesth, April 1, 2002; 49(4): 369 - 374.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Canadian Anesthesiologists' Society.